HC Wainwright & Co. Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $94
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and raised the price target from $87 to $94.
June 26, 2024 | 10:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on ANI Pharmaceuticals and raised the price target from $87 to $94, indicating confidence in the company's future performance.
The raised price target and maintained Buy rating from a reputable analyst firm suggest positive expectations for ANI Pharmaceuticals' future performance. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100